NeoGenomics, Inc. (NASDAQ:NEO) Insider Sells $450,128.60 in Stock – TheOlympiaReport
NeoGenomics, Inc. (NASDAQ:NEO) insider George Cardoza sold 19,444 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $23.15, for a total value of $450,128.60. Following the completion of the sale, the insider now owns 345,275 shares in the company, valued at approximately $7,993,116.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
George Cardoza also recently made the following trade(s):
- On Wednesday, November 6th, George Cardoza sold 51,556 shares of NeoGenomics stock. The shares were sold at an average price of $22.82, for a total value of $1,176,507.92.
Shares of NASDAQ NEO traded up $0.03 during trading hours on Thursday, reaching $23.48. 570,300 shares of the stock were exchanged, compared to its average volume of 986,057. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of 180.62 and a beta of 0.94. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.05 and a current ratio of 4.24. NeoGenomics, Inc. has a 52 week low of $11.05 and a 52 week high of $26.89. The stock’s fifty day simple moving average is $20.77 and its 200 day simple moving average is $22.58.
NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, October 29th. The medical research company reported $0.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.01. The company had revenue of $104.70 million for the quarter, compared to analyst estimates of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. The firm’s quarterly revenue was up 51.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.05 earnings per share. Research analysts predict that NeoGenomics, Inc. will post 0.19 EPS for the current fiscal year.
Several research firms have issued reports on NEO. Raymond James upped their price objective on NeoGenomics from $23.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, July 31st. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. Benchmark set a $27.00 target price on NeoGenomics and gave the stock a “buy” rating in a research note on Wednesday, July 31st. William Blair reiterated an “outperform” rating on shares of NeoGenomics in a research note on Tuesday, October 29th. Finally, Needham & Company LLC increased their target price on NeoGenomics from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $24.86.
Hedge funds and other institutional investors have recently made changes to their positions in the company. NEXT Financial Group Inc grew its position in NeoGenomics by 200.0% during the second quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock worth $59,000 after buying an additional 1,800 shares in the last quarter. Captrust Financial Advisors acquired a new stake in shares of NeoGenomics in the 2nd quarter valued at $66,000. Nisa Investment Advisors LLC boosted its holdings in shares of NeoGenomics by 867.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,870 shares of the medical research company’s stock valued at $74,000 after purchasing an additional 3,470 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of NeoGenomics by 75.0% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 4,550 shares of the medical research company’s stock valued at $87,000 after purchasing an additional 1,950 shares in the last quarter. Finally, Winslow Evans & Crocker Inc. acquired a new stake in shares of NeoGenomics in the 2nd quarter valued at $92,000. Institutional investors own 84.48% of the company’s stock.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Story: What are different types of coverage ratios?
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source